Article | July 21, 2015

Increase In HPAPI Manufacturing Highlights Need For Containment And Isolation Systems

Source: Gerteis Maschinen + Processengineering AG
Increase In HPAPI Manufacturing Highlights Need For Containment And Isolation Systems

An estimated 25 percent of globally manufactured drugs contain highly potent active pharmaceutical ingredients (HPAPIs). HPAPI drugs, which include small-molecule and biologic compounds as well as antibodydrug conjugates (ADCs), are often used in the treatment of cancer. The fastest growing segment of the HPAPI market are ADCs, a new class of therapeutic agents that deliver cytotoxic drugs selectively to antigen-expressing tumor cells. Non-oncology HPAPI compounds include hormones, narcotics, and retinoids.

Because HPAPI compounds are more selective and require relatively small dosages, they offer many therapeutic advantages over their lower potency counterparts. As a result, the global market for HPAPI drugs is expected to grow by an estimated compound annual growth rate of 9.9 percent in the next three years (2015-2018).